Blog
RSS FeedPosted by Michael Wonder on 20 Sep 2024
Dupixent (dupilumab) recommended for EU approval by the CHMP to treat eosinophilic oesophagitis in children as young as 1 year old
20 September 2024 - Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved ...
Posted by Michael Wonder on 20 Sep 2024
AbbVie receives positive CHMP opinion for mirvetuximab soravtansine (Elahere) for the treatment of certain adult ovarian cancer
20 September 2024 - AbbVie today announced that the EMA's CHMP has adopted a positive opinion recommending the marketing authorisation of ...
Posted by Michael Wonder on 20 Sep 2024
Fosdenopterin hydrobromide for the treatment of patients molybdenum cofactor deficiency type A
19 September 2024 - The Department of Health and Social Care has NICE to produce guidance on the use of ...
Posted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia. ...
Posted by Michael Wonder on 18 Sep 2024
EMA publishes agenda for 16-19 September 2024 CHMP meeting
16 September 2024 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 17 Sep 2024
ICER to assess treatment for retinitis pigmentosa
17 September 2024 - Report will be subject of New England CEPAC meeting in April 2025; draft scoping document open ...
Posted by Michael Wonder on 17 Sep 2024
Rozanolixizumab for the treatment of patients with generalised antibody positive myasthenia gravis
13 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance ...
Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 12 Sep 2024
Empagliflozin for the treatment of adolescents with type 2 diabetes mellitus
12 September 2024 - NICE is unable to make a recommendation on the use of empagliflozin (Jardiance) in the NHS for ...
Posted by Michael Wonder on 12 Sep 2024
Futibatinib for previously treated patients with advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
11 September 2024 - NICE has published final evidence-based recommendations on futibatinib (Lytgobi) for previously treated advanced cholangiocarcinoma with FGFR2 ...
Posted by Michael Wonder on 12 Sep 2024
Faricimab for the treatment of patients with visual impairment caused by macular oedema after retinal vein occlusion
11 September 2024 - NICE has published final evidence-based recommendations on the use of faricimab (Vabysmo) for the treatment of ...
Posted by Michael Wonder on 11 Sep 2024
Exagamglogene autotemcel for the treatment of patients 12 years of age and older with transfusion-dependent beta-thalassaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of exagamglogene autotemcel (Casgevy) for the treatment ...
Posted by Michael Wonder on 11 Sep 2024
HTA review outlines First Nations, pediatric reform and quick, cheap medicine
10 September 2024 - A Government review of Australia’s systems for accessing medicine has said it could slash waiting times ...
Posted by Michael Wonder on 11 Sep 2024
Evinacumab for the treatment of patients 12 years of age and older with homozygous familial hypercholesterolaemia
11 September 2024 - NICE has published final evidence-based recommendations on the use of evinacumab (Evkeeza) for the treatment of ...